Boston Scientific is a global medical technology company that specializes in the development, manufacturing, and marketing of a wide range of medical devices and solutions. The company focuses on providing innovative therapies for various medical conditions, including those affecting the cardiovascular, urology, and gastrointestinal systems, among others. Boston Scientific is committed to advancing patient care through its pioneering technologies, which are designed to improve outcomes and enhance the quality of life for patients around the world. Their product offerings include devices for minimally invasive procedures, enabling healthcare professionals to deliver high-quality care efficiently and effectively. Read More
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025 and February 3, 2026, both dates inclusive (the “Class Period”), have until May 4, 2026 to seek appointment as lead plaintiff of the Boston Scientific class action lawsuit. Captioned Troike v. Boston Scientific Corporation, No. 26-cv-40075 (D. Mass.), the Boston Scientific class action lawsuit charges Boston Scientific and certain of Boston Scientific’s top executives with violations of the Securities Exchange Act of 1934.
Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 4, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) securities between July 23, 2025 and February 3, 2026, inclusive (the “Class Period”).
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
The global absorbable hydrogel tissue spacer market, used primarily in prostate cancer radiation therapy , is gaining momentum as healthcare providers increasingly adopt technologies designed to reduce treatment side effects while improving patient outcomes.
Law Offices of Howard G. Smith reminds investors of the upcoming May 4, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) securities between July 23, 2025 and February 3, 2026, inclusive (the “Class Period”).
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Boston Scientific (BSX) To Contact Him Directly To Discuss Their Options
Levi & Korsinsky, LLP alerts investors in Boston Scientific Corporation (NYSE: BSX) of a pending securities class action. Class Period: July 23, 2025 through February 3, 2026. Check if you can recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.
As of March 10, 2026, the United States financial markets are witnessing an unprecedented explosion in Mergers and Acquisitions (M&A) that has caught even the most optimistic analysts by surprise. Driven by a historic surge in private equity confidence—now sitting at a six-year high of 86%—the deal-making
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Boston Scientific Corporation. (“Boston Scientific” or the “Company”) (NYSE: BSX) securities between July 23, 2025 and February 3, 2026, inclusive (the “Class Period”). Boston Scientific investors have until May 4, 2026 to file a lead plaintiff motion.
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive.
The U.S. Mergers and Acquisitions (M&A) landscape has entered a blistering new phase of activity, shaking off the volatility of the mid-2020s to reach levels of engagement not seen in over half a decade. Driven by a historic flood of "dry powder" and a rapidly stabilizing macroeconomic environment,
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) securities between July 23, 2025 and February 3, 2026, inclusive (the “Class Period”). Boston Scientific investors have until May 4, 2026 to file a lead plaintiff motion.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or “the Company”) (NYSE: BSX) for violations of the securities laws.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) securities between July 23, 2025 and February 3, 2026, inclusive (the “Class Period”). Boston Scientific investors have until May 4, 2026 to file a lead plaintiff motion.
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive.
